FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033081617> ?p ?o ?g. }

• W2033081617 endingPage "1256.e6" @default.
• W2033081617 startingPage "1246" @default.
• W2033081617 abstract "The Food and Drug Administration (FDA) is moving from the Crohn's Disease Activity Index to patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs will become an important aspect of assessing activity of inflammatory bowel disease (IBD) and for labeling specific drugs for this disease. PROs always have been considered in the management of patients with rheumatoid arthritis or multiple sclerosis, and have included measurements of quality of life, disability, or fatigue. Several disease-specific scales have been developed to assess these PROs and commonly are used in clinical trials. Outcomes reported by patients in clinical trials of IBD initially focused on quality of life, measured by the Short-Form 36 questionnaire or disease-specific scales such as the Inflammatory Bowel Disease Questionnaire or its shorter version. Recently considered factors include fatigue, depression and anxiety, and work productivity, as measured by the Functional Assessment Chronic Illness Therapy-Fatigue, the Hospital Anxiety Depression, and the Work Productivity Activity Impairment Questionnaire, respectively. However, few data are available on how treatment affects these factors in patients with IBD. Although disability generally is recognized in patients with IBD, it is not measured. The international IBD disability index currently is being validated. None of the PROs currently used in IBD were developed according to FDA guidance for PRO development. PROs will be a major primary end point of future trials. FDA guidance is needed to develop additional PROs for IBD that can be incorporated into trials, to better compare patients' experience with different therapies." @default.
• W2033081617 created "2016-06-24" @default.
• W2033081617 creator A5042884495 @default.
• W2033081617 creator A5070672619 @default.
• W2033081617 creator A5083726032 @default.
• W2033081617 date "2014-08-01" @default.
• W2033081617 modified "2023-10-18" @default.
• W2033081617 title "Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease" @default.
• W2033081617 cites W132550693 @default.
• W2033081617 cites W1486102782 @default.
• W2033081617 cites W1555473009 @default.
• W2033081617 cites W1591334313 @default.
• W2033081617 cites W1595829166 @default.
• W2033081617 cites W1607808246 @default.
• W2033081617 cites W1607903620 @default.
• W2033081617 cites W1625912164 @default.
• W2033081617 cites W1669870 @default.
• W2033081617 cites W1671682816 @default.
• W2033081617 cites W1698939815 @default.
• W2033081617 cites W1757701388 @default.
• W2033081617 cites W1872442146 @default.
• W2033081617 cites W1934005616 @default.
• W2033081617 cites W1963569206 @default.
• W2033081617 cites W1964780014 @default.
• W2033081617 cites W1964785646 @default.
• W2033081617 cites W1965651011 @default.
• W2033081617 cites W1966772020 @default.
• W2033081617 cites W1970094285 @default.
• W2033081617 cites W1971774034 @default.
• W2033081617 cites W1974237426 @default.
• W2033081617 cites W1974456212 @default.
• W2033081617 cites W1979297670 @default.
• W2033081617 cites W1980206322 @default.
• W2033081617 cites W1981998074 @default.
• W2033081617 cites W1982677998 @default.
• W2033081617 cites W1985004174 @default.
• W2033081617 cites W1987785007 @default.
• W2033081617 cites W1988291071 @default.
• W2033081617 cites W1990497976 @default.
• W2033081617 cites W1992973534 @default.
• W2033081617 cites W1993140858 @default.
• W2033081617 cites W1994020662 @default.
• W2033081617 cites W1994311738 @default.
• W2033081617 cites W1994748256 @default.
• W2033081617 cites W1995345543 @default.
• W2033081617 cites W1995768930 @default.
• W2033081617 cites W1998609863 @default.
• W2033081617 cites W1998862882 @default.
• W2033081617 cites W2000500639 @default.
• W2033081617 cites W2001681806 @default.
• W2033081617 cites W2003239266 @default.
• W2033081617 cites W2003740532 @default.
• W2033081617 cites W2005355775 @default.
• W2033081617 cites W2005801660 @default.
• W2033081617 cites W2005855555 @default.
• W2033081617 cites W2007366091 @default.
• W2033081617 cites W2007422790 @default.
• W2033081617 cites W2019743387 @default.
• W2033081617 cites W2020640954 @default.
• W2033081617 cites W2024162533 @default.
• W2033081617 cites W2026877602 @default.
• W2033081617 cites W2029342034 @default.
• W2033081617 cites W2032797181 @default.
• W2033081617 cites W2033418160 @default.
• W2033081617 cites W2035172615 @default.
• W2033081617 cites W2035282943 @default.
• W2033081617 cites W2035551117 @default.
• W2033081617 cites W2039007892 @default.
• W2033081617 cites W2041388322 @default.
• W2033081617 cites W2047070488 @default.
• W2033081617 cites W2054456699 @default.
• W2033081617 cites W2055211617 @default.
• W2033081617 cites W2059775920 @default.
• W2033081617 cites W2063703049 @default.
• W2033081617 cites W2063931484 @default.
• W2033081617 cites W2065141771 @default.
• W2033081617 cites W2066244236 @default.
• W2033081617 cites W2067495470 @default.
• W2033081617 cites W2068853760 @default.
• W2033081617 cites W2068988582 @default.
• W2033081617 cites W2072013430 @default.
• W2033081617 cites W2074192733 @default.
• W2033081617 cites W2074840514 @default.
• W2033081617 cites W2076432696 @default.
• W2033081617 cites W2077833843 @default.
• W2033081617 cites W2080744226 @default.
• W2033081617 cites W2081383488 @default.
• W2033081617 cites W2086050457 @default.
• W2033081617 cites W2086325363 @default.
• W2033081617 cites W2089546540 @default.
• W2033081617 cites W2092863985 @default.
• W2033081617 cites W2093158866 @default.
• W2033081617 cites W2093375795 @default.
• W2033081617 cites W2093894520 @default.
• W2033081617 cites W2094855314 @default.
• W2033081617 cites W2104015736 @default.
• W2033081617 cites W2105011165 @default.
• W2033081617 cites W2107743584 @default.

• next